Hjem › Tripelnegativ brystkræft › Washington
Tripelnegativ brystkræft kliniske forsøg i Washington
20 studier for Tripelnegativ brystkræft søger deltagere på steder i Washington.
Byer i Washington
Officiel studietekst (engelsk)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- University of Washington, Fred Hutchinson Cancer Center, Seattle
RekruttererFase 1/2
Alder 12 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT04585750A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Fred Hutchinson Cancer Center ( Site 0069), Seattle
- Cancer Care Northwest ( Site 0003), Spokane
- Northwest Medical Specialties, PLLC ( Site 0067), Tacoma
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT06966700Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- Fred Hutchinson Cancer Center, Seattle
RekruttererObservationsstudie
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT04981119Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Northwest Medical Specialties, PLLC ( Site 0093), Tacoma
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT06393374A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Fred Hutchinson Cancer Center ( Site 0042), Seattle
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT06841354A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- Swedish Medical Center, Seattle
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 23. sep. 2026 · NCT06618287Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- University of Washington Fred Hutchinson, Seattle
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 21. sep. 2026 · NCT05983432First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
- Fred Hutchinson Cancer Center, Seattle
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 11. sep. 2026 · NCT06657222Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Providence Regional Cancer System, Lacey
- MultiCare Regional Cancer Center - Tacoma, Puyallup
- Northwest Medical Specialties, PLLC, Puyallup
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 9. sep. 2026 · NCT05633654Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
- Cancer Care Northwest, Spokane Valley
RekruttererObservationsstudie
Alder 18 til 99 · Alle køn · Opdateret 3. sep. 2026 · NCT07211178SMP-3124LP in Adults With Advanced Solid Tumors
- University of Washington, Seattle
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 12. aug. 2026 · NCT06526819A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer
- Fred Hutch/University of Washington Cancer Consortium, Seattle
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 4. aug. 2026 · NCT07078604Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Swedish Cancer Institute, Seattle
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 4. aug. 2026 · NCT05579366Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
- University Of Washington, Seattle
RekruttererFase 1
Alder 18 til 100 · Alle køn · Opdateret 29. jul. 2026 · NCT06562192A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
- Summit Cancer Center, Spokane
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 28. jul. 2026 · NCT06150664A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Fred Hutchinson Cancer Center, Seattle
- Summit Cancer Centers, Spokane
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 29. jun. 2026 · NCT05377996A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
- Medical Oncology Associates, Spokane
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 18. jun. 2026 · NCT07503808A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
- Fred Hutch Cancer Center, Seattle
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 9. sep. 2025 · NCT06682793A Study of NX-1607 in Adults With Advanced Malignancies
- Fred Hutchinson Cancer Center, Seattle
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 9. sep. 2025 · NCT05107674CtDNA Based MRD Testing for NAC Monitoring in TNBC
- Cancer Care Northwest, Spokane
RekruttererObservationsstudie
Alder 18 og opefter · Kvinder · Opdateret 7. jan. 2025 · NCT06230185Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.